CURE vs RXD: Leverage, Returns & Decay

Over three months to Nov 13, 2026, against its daily multiple, compounded, CURE finished 3.3 points short and RXD 2.1 points over.

Return gap
+101.2 pts1 year to Nov 13, 2026: CURE ahead, total return
Fee gap
0.01 ptsA year: CURE 0.94%, RXD 0.95%, per filings dated Mar 3, 2026 and Sep 25, 2026
Overlap
–No book read for both funds
Net flow
−$7m / −$122kCURE / RXD, Oct 13, 2026 to Nov 12, 2026, daily basis
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
CURE and RXD · 1 year

Growth of 100

CURE +65.7%RXD −35.5%
Growth of 100 in CURE and RXD over 1 year, Nov 13, 2025 to Nov 13, 2026, with distributions reinvested. CURE ends at 165.7 (+65.7%), RXD at 64.5 (−35.5%).

CURE +65.7%, RXD −35.5%: CURE +101.2 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.

Share

Use this comparison

Alert

CURE and RXD flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag the order size

Cost to trade

Hypothetical. A $10,000 order in RXD costs about $10.50 one way and $21.00 in and out, at a median spread of 0.21%. The 0.21% spread is RXD’s 30-day median, from ProShares (fund page).

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in RXD for 10 years at 0.95% a year costs about $1,542 in fees and lost growth; CURE at 0.94% would cost $1,526. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

CURE · 3 months to Nov 13, 20261.7 pts short of its stated multiple
1.7 pts short of its stated multipleCURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×3 implies+39.9%CURE returned+38.2%1.7 pts short of its stated multipleCURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×3 implies+39.9%CURE returned+38.2%

CURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.

Data from Aug 14, 2026 to Nov 13, 2026.
RXD · 3 months to Nov 13, 20264.5 pts ahead of its stated multiple
4.5 pts ahead of its stated multipleRXD returned −22.1% while −2 times XLV's move would have been −26.6%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×−2 implies−26.6%RXD returned−22.1%4.5 pts ahead of its stated multipleRXD returned −22.1% while −2 times XLV's move would have been −26.6%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×−2 implies−26.6%RXD returned−22.1%

RXD returned −22.1% while −2 times XLV's move would have been −26.6%. Data from Aug 14, 2026 to Nov 13, 2026.

RXD returned −22.1% while −2 times XLV's move would have been −26.6%. Data from Aug 14, 2026 to Nov 13, 2026.

IQ Leverage Score

How closely it delivered its daily multiple over 3 months, ranked against 31 leveraged ETFs at 3x, over three months and 74 inverse ETFs at 2x, over three months. 100 is best.

RXD scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?

CURE among the 31 leveraged ETFs at 3x, over three months

1.6, the lowest in this set98.4, the highest

RXD among the 74 inverse ETFs at 2x, over three months

0.7, the lowest in this set99.3, the highest

A percentile among the 31 leveraged ETFs at 3x, over three months. RXD is a percentile among the 74 inverse ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.

Key numbers

CURE returned, 3 months
+38.2%
RXD returned, 3 months
−22.1%
CURE from its stated multiple: compounding +1.6 pts, gap to the daily multiple −3.3 pts
−1.7 pts
RXD from its stated multiple: compounding +2.4 pts, gap to the daily multiple +2.1 pts
+4.5 pts

CURE costs 0.01 points a year less; their one-year returns differ by 101.2 points; CURE is far larger, $209m against $2.8m.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+65.7%−35.5%
What its daily multiple gave, 3 months41.5%−24.2%
What the underlying did, 3 monthsXLV 13.3%XLV 13.3%
What the underlying did, 3 monthsXLV 13.3%XLV 13.3%
What it tracksHealthcareHealth Care
Expense ratio0.94%0.95%
Net assets, as of Nov 12, 2026$209m$2.8m
Holdings in commonnot published

The numbers behind it

Net assets: $209m on Nov 12, 2026 for Direxion Daily Healthcare Bull 3X ETF, and $2.7m on Nov 13, 2026 for ProShares UltraShort Health Care.

Side by side

Open the table
FundDirexion Daily Healthcare Bull 3X ETF · Aims to return three times the daily move of health care (XLV)ProShares UltraShort Health Care · Aims to return twice the opposite of the daily move of health care (XLV)
IssuerDirexionProShares
Sets out to return+3x−2x
Underlying assetXLVXLV
Segmentsectorsector
Fund returned, 3 months+38.2%−22.1%
Underlying returned, over that window+13.3%+13.3%
What the stated multiple implies, over that window+39.9%−26.6%
Difference from stated, over that window−1.7 pts+4.5 pts
Fund returned, 1 year+65.7%−35.5%
Difference from stated, over that window−11.4 pts+15.9 pts
Underlying volatility19%19%
Expense ratio0.94%0.95%
First tradedJun 15, 2011Feb 1, 2007
Net assets, CURE as of Nov 12, 2026 and RXD as of Nov 13, 2026$209m$2.7m

As of Nov 13, 2026. Source: ETFIQ.

The dataFull tables, method and files, one click away.

Window by window

Open the full table
1 month+25.9%−15.7%+25.8%−17.2%+0.1 pts+1.5 pts
3 months+38.2%−22.1%+39.9%−26.6%−1.7 pts+4.5 pts
6 months+104.8%−42.0%+93.6%−62.4%+11.2 pts+20.4 pts
1 year+65.7%−35.5%+77.1%−51.4%−11.4 pts+15.9 pts
3 years+117.4%−51.8%+165.6%not meaningful−48.2 ptsnot meaningful
Since launch (Not the same days: CURE Jun 2011 · RXD Feb 2007)+3,894.1%−99.5%not meaningfulnot meaningfulnot meaningfulnot meaningful

About CURE

Over the three months to Nov 13, 2026, CURE returned 38.2%, against 41.5% for three times XLV's daily moves. Read the multiple against the whole window instead and 3 times XLV's 13.3% implies +39.9%, which makes CURE look 1.7 points short. That is not the fund's objective, which is daily. Of that 1.7, daily compounding is +1.6 points, which any 3 times fund would show over the same path, and the fund itself is −3.3 points against 3 times each day's move, compounded. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not +3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XLV moved at 19% annualized over that window. The more it moves, the further the two numbers separate.

About RXD

Over the three months to Nov 13, 2026, RXD lost 22.1%, against −24.2% for twice the inverse of XLV's daily moves. Read the multiple against the whole window instead and −2 times XLV's 13.3% implies −26.6%, which makes RXD look 4.5 points over. Of that 4.5, daily compounding is +2.4 points, which any −2 times fund would show over the same path, and the fund itself is +2.1 points against −2 times each day's move, compounded. RXD aims to return -2 times XLV's move each day, then resets. Over longer periods the daily results compound, so the total is not -2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.

Questions people ask

Which came closer to its daily multiple, CURE or RXD?

Over the window to Nov 13, 2026, CURE finished 1.7 points from what its multiple implies and RXD finished 4.5 points from its own, so CURE came closer. Neither number predicts the next window: it depends on how much the underlying moves about.

Are CURE and RXD levered on the same thing?

Yes. Both are levered on health care, CURE at +3 times and RXD at -2 times the daily move.

Which one decays faster, CURE or RXD?

Decay follows how much the underlying moves about. Over this window CURE’s moved at 19% annualized and RXD’s at 19%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.

Can I hold CURE or RXD for a year?

Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.

Which is cheaper, CURE or RXD?

CURE charges 0.94% a year and RXD charges 0.95%, so CURE is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, CURE against RXD, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/cure-vs-rxd

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.